A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

BACKGROUND: Vilazodone, a selective serotonin reuptake inhibitor and 5-HT(1A) receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorde...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Depress Anxiety
Asıl Yazarlar: Gommoll, Carl, Durgam, Suresh, Mathews, Maju, Forero, Giovanna, Nunez, Rene, Tang, Xiongwen, Thase, Michael E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2015
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676920/
https://ncbi.nlm.nih.gov/pubmed/25891440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/da.22365
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller